Semivoluntary movement (=unvoluntary)

Size: px
Start display at page:

Download "Semivoluntary movement (=unvoluntary)"

Transcription

1 EXTRAPYRAMIDAL DISORDERS = Movement disorders = Degenerative disease 1

2 4 types of movements: Voluntary movement Semivoluntary movement (=unvoluntary) Involuntary movement Automatic movement 2

3 3

4 Movement disorders = Extrapyramidal disorder Disorder of regulation of voluntary motoric activity without direct influence towards muscle strength, sensibility, or cerebellum. 4

5 Extrapyramidal disorder Hyperkinetic disorder: abnormal involuntary movements Hypokinetic disorder: reduction of movements. = Movement disorders are caused by dysfunction of basal ganglia 5

6 Basal ganglia: Caudate nucleus Putamen Globus pallidus Subthalamic nucleus Substantia nigra 6

7 Diseases & syndrome with abnormal movements: Essential tremor (familial / benign) Parkinsonism Progressive supranuclear palsy Idiopathic torsion dystonia Chorea sydenham Sindroma Gilles de la Tourette Drug-induced movement disorders, etc. 7

8 Parkinsonism = Parkinson syndrome 1. Primary / Idiopathic = Paralysis agitans = Parkinson disease 2. Secondary/Symptomatic = Causes: - arteriosclerosis - anoxia /cerebral ischemia - drugs - toxic agent - encephalitis etc. 8

9 Parkinsonism (CON T) 3. Paraparkinson / Parkinson plus - Wilson disease - Huntington disease - Normotensive Hydrocephalus 9

10 Parkinson disease = Parkinson idiopathic = Paralysis agitans - Most commonly be found - Middle age to old age 10

11 Etiology and pathogenesis The certain Etiology is unknown PD is due to cells degeneration dopamine decreased in substantia nigra 11

12 ACh DA I DA ACh I ACh i DA 12

13 Hypotesis: Aging process: dopaminergic neuronal death!!! anti oxydative-protective mechanism decreased Environmental toxin: - heavy metal (Iron, Zinc, mercury etc) - MPTP Genetic sensitivity Oxydative stress: dopamine reaction free radicals 13

14 Pathology Cutting of mid-brain: degeneration & neuronal death which contain melanin in substansia-nigra. Microscopic: In compacta zone: - Most of neuron are loss - Residual : containings Lewy-bodies 14

15 Lewy bodies in subst.nigra: 15

16 Clinical findings. Triad of symptoms: - rigidity - tremor - bradikinesis 1. tremor: - pill rolling tremor - during tension!!!, sleep - disappear - resting tremor = Parkinsonian tremor 16

17 Clinical findings (Con t) 2. Rigidity : cogwheel phenomenon. 3. Bradikinese 4. Weakness & fatique 5. Dystonia 6. Parkinsonian facies mask-like 7. Micrographia 8. Gait: Festinant gait = Parkinsonian gait 17

18 Clinical findings (con t) 9. freezing: late stage, suddlenly stop walking 10. Slowly speaking and monotone 11. Eye movements: - lack of blinking - eye movement disturb. - Glabella reflex (+) 12. Pain: paresthesia of limbs 18

19 Clinical findings (con t) 13. ANS disturbance: - salivary / excessive sweating -urinary incontinence etc. 14. Saliva!!! sialorrhea 15. Hypotension orthostatic hypotension 16. Depression 17. Dementia 19

20 Gait: 20

21 Tremor: 21

22 Rising: 22

23 Sitting: 23

24 Hypomimia: 24

25 Retropulsion: 25

26 Freezing: 26

27 Diagnostic procedure Diagnosis is made clinically based on clinical symptoms found EEG examination : may show diffuse slow wave MRI & CT Scan : may show cortical atrophy. 27

28 Treatment It is considered: due to dopamine deficiency in CNS. 1. Levodopa 2. Anticholinergic drugs: trihexyphenidyl 3. Antihistamine: diphenhydramine 4. Bromocriptine 5. Amantadine 6. Selegiline 28

29 TH DD L-tyrosine l-dopa DA TH: tyrosine hydroxylase DD: dopa-decarboxylase DA located outside vesicles will be catalyzed by enzymes : MAO(monoamine-oxydase) inside the neuron cell COMT(catechol-o-methyl-transferase) outside the neuron cell. 29

30 In peripheral : 1. l-dopa dopamine I dopa-decarboxylase v ^ dopa-decarboxylase inhibitor = carbidopa sinemet = benserazide madopar b 30

31 2. l-dopa dopamine I catechol-o-methyltransferase (COMT) v ^ COMT inhibitor : - tolcapone - entacapone 31

32 Prognosis: The prognosis is still poor. 32

33 Diseases & syndromes with abnormal movements : Essential tremor (familial / benign) Parkinsonism Progressive supranuclear palsy Idiopathic torsion dystonia Chorea sydenham Sindroma Gilles de la Tourette Drug-induced movement disorders, etc. 33

34 Parkinsonism = Parkinson syndrome 1. Primary/ Idiopathic = Paralysis agitans = Parkinson disease 2. Secondary / Symptomatic = Well known causes : - arteriosclerosis - anoxia / cerebral ischemia - drugs - toxic agents - encephalitis, etc. 34

35 Parkinsonism (Con t) 3. Paraparkinson / Parkinson plus - Wilson disease - Huntington disease - Normotensive Hydrocephalus 35

36 ESSENTIAL TREMOR Familial tremor Benign tremor Autosomal dominant Begin at teen-agers or young adults 36

37 Tremor usually affect one or both hands, head and voices, whereas foot is not affected. Neurological assessments show no other abnormality. Despite the longer the tremor the clearer the symptoms, usually it does not disturb,but the patient feels ashamed. 37

38 Sometimes it disturbs fine and difficult movements, writing and speaking when laryngeal muscle is involved. Consuming small amount of alcohol temporary improvement is reported, but the mechanism has not been known yet. 38

39 Treatment - Diazepam 6 15 mg per day - Propranolol mg per day - Primidone - Alprazolam - Not responsive: # thalamotomy # thalamic stimulation 39

40 CHOREA SYDENHAM Affecting children and young adults resulting from complication of streptococcus hemolytic A infection and the possible basic pathological features is arteritis. Approximately 30% of cases occur 2 or 3 months following rheumatoid fever or polyarthritis, the rest without such historys. 40

41 Onset can be acute or gradually within 4-6 months, can also occur during pregnancy or oral contraceptive users. Symptoms including abnormal chorea movements, sometimes unilaterally in mild cases. Changes of behavior In children may reveal easily to anger and doughty Labile of emotions 41

42 In 30% of cases involves the heart Treatment: bed rest, sedatives, prophylaxis antibiotics even though without acute rheumatoid fever. Penicillin injection to be continued orally until 20 years of age to prevent staphylococcal infection. The prognosis basically lies on the complication of the heart. 42

43 Drug-induced movement disorders 1. Parkinsonism 2. Acute dystonia or dyskinesis 3. Akathisia 4. Tardive dyskinesis 5. Neuroleptic malignant syndrome 6. Others. 43

44 Parkinsonism. Complication of dopamine receptor inhibitor drugs: - phenothiazine - butyrophenone - thioxanthene - metoclopramide 44

45 Parkinsonism (Con t) Symptoms : - rigidity - mask-like face - bradykinesis - tremor (seldom) Treatment : - Discontinue the drug - anti-cholinergic drugs (trihexyphenidyl) 45

46 Acute dystonia / dyskinesia blepharospasm torticollis facial grimacing following phenothiazine administration. Treatment: Intravenous anti-cholinergicdrug (benztropine 2 mg or diphenhydramine 50 mg). 46

47 Blepharospasm 47

48 Akathisia Motoric restlessness, compulsion to move or inability to sit still for more than a short period of time, keep standing or walking. Receiving phenothiazine Treatment: - Lowering the dose if possible - propranolol mg/hari - anticholinergic drugs / benzodiazepines 48

49 Tardive dyskinesia Repetitive involuntary movements of the mouth, tongue and lips, occasionally accompanied by dystonic posturing or choreoathetotic movements of trunk and limbs. Mostly following administration of neurolep tic, metoclopramide, antihistamines, tricyclic antidepressant and chronic alcohol abuse. 49

50 50

51 Tardive dyskinesia (Con t) Treatment: - Dopamine antagonists : haloperidol - Catecholamine-depleting agents: reserpine, tetrabenazine. - Baclofen - Calcium channel blocking agents - Vitamin E, etc. 51

52 Neuroleptic malignant syndrome An acute idiosyncratic reaction to - neuroleptic medication due to central dopamine receptor blockade. May also originate from non-neurololeptic drugs: metoclopramide, domperidone, amphetamines, reserpine, tetrabenazine, tricyclic antidepressants with lithium or with MAO inhibitor and withdrawal of antiparkinsonian medication. 52

53 Neuroleptic malignant syndrome(con t) The use of cocaine and 3.4 methy- lene dioxymethamphetamine (MDMA) = Ecstasy Symptoms are usually abrupt in onset, fever, encephalopathy with fluctuating confusion and agitation progressing to coma, labile BP, tachycardia, diaphoresis in association with dystonia and tremor. The couse is often rapid in untreated cases wit deterioration leading to cardiac failure, pulmonary congestion, pneumonia, renal failure and death. 53

54 Neuroleptic malignant syndrome (Con t) Treatment: - Discontinue the neuroleptic drugs - Control of body temperature - Monitor the BP, urine, electrolytes, temperature change - Administer bromocriptine mg/day by NGT - Dantrolene sodium i.v and convert to oral as improvement occurs. 54

55 Others: Levodopa various abnormal movement is related to dosage. Bromocriptine, anticholinergic drugs, phenytoin, carbamazepine, amphetamine, lithium and oral contraceptive may also result in chorea ect. 55

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Sirilak yimcharoen Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

Professor Tim Anderson

Professor Tim Anderson Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning

More information

Movement Disorders. Eric Kraus, MD! Neurology!

Movement Disorders. Eric Kraus, MD! Neurology! Movement Disorders Eric Kraus, MD! Neurology! Classify Bradykinesia! Tic! Myoclonus! Tremor! Dystonia! Athetosis! Chorea! Ballismus! Case 1 This 64 year-old female has had progression of a tremor over

More information

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological

More information

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there

More information

Parts of the motor circuits

Parts of the motor circuits MOVEMENT DISORDERS Parts of the motor circuits cortical centers: there are centers in all the cortical lobes subcortical centers: caudate nucleus putamen pallidum subthalamical nucleus (Luys) nucleus ruber

More information

Basal ganglia Sujata Sofat, class of 2009

Basal ganglia Sujata Sofat, class of 2009 Basal ganglia Sujata Sofat, class of 2009 Basal ganglia Objectives Describe the function of the Basal Ganglia in movement Define the BG components and their locations Describe the motor loop of the BG

More information

Identification number: TÁMOP /1/A

Identification number: TÁMOP /1/A Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master s Programmes at the University of Pécs and at the University of Debrecen Identification

More information

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually

More information

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -

More information

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010 Extrapyramidal Motor System Basal Ganglia or Striatum Descending extrapyramidal paths receive input from other parts of motor system: From the cerebellum From the basal ganglia or corpus striatum Caudate

More information

Martin A. Samuels, M.D. MOVEMENT DISORDERS

Martin A. Samuels, M.D. MOVEMENT DISORDERS Martin A. Samuels, M.D. MOVEMENT DISORDERS I. Nomenclature of Movement Disorders A. Too Little Movement 1. Paralysis (paresis) 2. Rigidity a. spasticity (pyramidal) b. "lead pipe" (extra pyramidal) c.

More information

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits

More information

Movement Disorders: A Brief Overview

Movement Disorders: A Brief Overview Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance

More information

Professor Tim Anderson

Professor Tim Anderson Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition

More information

Parkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology

Parkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology Parkinson's Disease Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology 18 February 2002 Parkinson Disease Neurological disease affecting over four million patients

More information

Margo J Nell Dept Pharmacology

Margo J Nell Dept Pharmacology Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce

More information

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS

More information

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) 475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive

More information

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non

More information

A. General features of the basal ganglia, one of our 3 major motor control centers:

A. General features of the basal ganglia, one of our 3 major motor control centers: Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. April 22, 2010 THE BASAL GANGLIA Objectives: 1. What are the

More information

The motor regulator. 1) Basal ganglia/nucleus

The motor regulator. 1) Basal ganglia/nucleus The motor regulator 1) Basal ganglia/nucleus Neural structures involved in the control of movement Basal Ganglia - Components of the basal ganglia - Function of the basal ganglia - Connection and circuits

More information

A. General features of the basal ganglia, one of our 3 major motor control centers:

A. General features of the basal ganglia, one of our 3 major motor control centers: Reading: Waxman pp. 141-146 are not very helpful! Computer Resources: HyperBrain, Chapter 12 Dental Neuroanatomy Suzanne S. Stensaas, Ph.D. March 1, 2012 THE BASAL GANGLIA Objectives: 1. What are the main

More information

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements BASAL GANGLIA Chris Cohan, Ph.D. Dept. of Pathology/Anat Sci University at Buffalo I) Overview How do Basal Ganglia affect movement Basal ganglia enhance cortical motor activity and facilitate movement.

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y

Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y Educational Objectives Improved history taking in patients with movement disorders. Develop a systematic approach to observing and describing

More information

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease 5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater

More information

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,

More information

movement disorders for psychiatrists

movement disorders for psychiatrists Movement disorders for psychiatrists Nandakumar Narayanan Assistant Professor, Neurology University of Iowa Thanks to Dr. Rodnitkzy Funding for my lab National Institutes of Health Carver Medical Trust

More information

ANTIPARKINSONIAN DRUGS. DRUGs ACT ON CNS (Pharmacology) Unit-5(8)

ANTIPARKINSONIAN DRUGS. DRUGs ACT ON CNS (Pharmacology) Unit-5(8) ANTIPARKINSONIAN DRUGS DRUGs ACT ON CNS (Pharmacology) Unit-5(8) Parkinsonism (PD) Extrapyramidal motor function disorder characterized by Rigidity Tremor Hypokinesia/Bradykinesia Impairment of postural

More information

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types Background Movement Disorders Psychology 372 Physiological Psychology Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Early Studies Found some patients with progressive weakness

More information

Evaluation and Management of Parkinson s Disease in the Older Patient

Evaluation and Management of Parkinson s Disease in the Older Patient Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of

More information

Drugs used in Parkinsonism

Drugs used in Parkinsonism Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your

More information

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives

Parkinson s Disease. Patients will ask you. 8/14/2015. Objectives Parkinson s Disease Jean Van Kingsley MS, FNP-BC Objectives Describe the pathophysiolgy of PD. Review clinical charachteristics of PD. Identify management strategies, to maximize functional status. Recognize

More information

Optimizing Clinical Communication in Parkinson s Disease:

Optimizing Clinical Communication in Parkinson s Disease: Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of

More information

Chapter 161 Antipsychotics

Chapter 161 Antipsychotics Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in

More information

8/28/2017. Behind the Scenes of Parkinson s Disease

8/28/2017. Behind the Scenes of Parkinson s Disease BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic

More information

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug

More information

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential

More information

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing

More information

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging Dr. Olav E. Krigolson krigolson@uvic.ca Lecture 5: PARKINSONS DISEASE The Basal Ganglia Primary motor cortex Execution of movement

More information

Neurodegenerative diseases

Neurodegenerative diseases Neurodegenerative diseases Hiwa K. Saaed, PhD Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani Hiwa.saaed@univsul.edu.iq 2018-19 Neurodegenerative diseases of the CNS

More information

COALINGA STATE HOSPITAL. Effective Date: August 31, 2006

COALINGA STATE HOSPITAL. Effective Date: August 31, 2006 COALINGA STATE HOSPITAL NURSING POLICY AND PROCEDURE MANUAL SECTION Emergency Procedures POLICY NUMBER: 717 Effective Date: August 31, 2006 SUBJECT: NEUROLEPTIC MALIGNANT SYNDROME 1. PURPOSE: To provide

More information

Department of Neurology, Rigshospitalet, 9 Blegdamsvej, PAULSON, O.B. Involuntary Movements. Tohoku J. Exp. Med., 1990, 161,

Department of Neurology, Rigshospitalet, 9 Blegdamsvej, PAULSON, O.B. Involuntary Movements. Tohoku J. Exp. Med., 1990, 161, Tohoku J. Exp. Med., 1990, 161, Suppl., 21-27 Involuntary Movements OLAF B. PAULSON Department of Neurology, Rigshospitalet, 9 Blegdamsvej, DK-2100, Copenhagen, Denmark PAULSON, O.B. Involuntary Movements.

More information

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age

More information

Involuntary Movements in Children and Adolescents: Is it Seizure, Tic or Something Else?

Involuntary Movements in Children and Adolescents: Is it Seizure, Tic or Something Else? Involuntary Movements in Children and Adolescents: Is it Seizure, Tic or Something Else? California Association of Nurse Practitioners Monterey, March 22, 2013 Julie Sprague-McRae, MS, RN, PPCNP-BC Ruth

More information

An approach to movement disorders. Kailash Bhatia, DM, FRCP Professor of Clinical Neurology Institute of Neurology Queen Square, London

An approach to movement disorders. Kailash Bhatia, DM, FRCP Professor of Clinical Neurology Institute of Neurology Queen Square, London An approach to movement disorders Kailash Bhatia, DM, FRCP Professor of Clinical Neurology Institute of Neurology Queen Square, London Neurology Diagnosis Two main questions: What parts of the nervous

More information

Differential Diagnosis of Hypokinetic Movement Disorders

Differential Diagnosis of Hypokinetic Movement Disorders Differential Diagnosis of Hypokinetic Movement Disorders Dr Donald Grosset Consultant Neurologist - Honorary Professor Institute of Neurological Sciences - Glasgow University Hypokinetic Parkinson's Disease

More information

Parkinson s Disease Update

Parkinson s Disease Update Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms

More information

Strick Lecture 4 March 29, 2006 Page 1

Strick Lecture 4 March 29, 2006 Page 1 Strick Lecture 4 March 29, 2006 Page 1 Basal Ganglia OUTLINE- I. Structures included in the basal ganglia II. III. IV. Skeleton diagram of Basal Ganglia Loops with cortex Similarity with Cerebellar Loops

More information

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with

More information

Extrapyramidal Symptoms Associated with Antipsychotic Use

Extrapyramidal Symptoms Associated with Antipsychotic Use Extrapyramidal Symptoms Associated with Antipsychotic Use Tamara Pringsheim, MD, FRCPC, FAAN Associate Professor, University of Calgary Department of Clinical Neurosciences, Psychiatry, Pediatrics and

More information

Parkinson s Disease Current Treatment Options

Parkinson s Disease Current Treatment Options Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority

More information

Parkinson s Disease and Its Treatment

Parkinson s Disease and Its Treatment Parkinson s Disease and Its Treatment By H. David Bergman, Ph.D. Dean, Southwestern Oklahoma State University, College of Pharmacy Goals and Objectives Goals: To provide the pharmacist with information

More information

MOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement

MOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement MOVEMENT 2 Dr. Steinmetz 3 OUTLINE The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement Parkinson s Disease Huntington s Disease 1 4 TYPES

More information

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a

More information

Drugs Affecting the Central Nervous System

Drugs Affecting the Central Nervous System Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease

More information

Basal Ganglia. Today s lecture is about Basal Ganglia and it covers:

Basal Ganglia. Today s lecture is about Basal Ganglia and it covers: Basal Ganglia Motor system is complex interaction between Lower motor neurons (spinal cord and brainstem circuits) and Upper motor neurons (pyramidal and extrapyramidal tracts) plus two main regulators

More information

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available

More information

PARKINSON S MEDICATION

PARKINSON S MEDICATION PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development

More information

Alison Charleston 1 st September 2016

Alison Charleston 1 st September 2016 Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence

More information

March 2004 Parkinson s Disease H01

March 2004 Parkinson s Disease H01 W-F Professional Associates, Inc. 400 Lake Cook Rd., Suite 207 Deerfield, IL 60015 847-945-8050 March 2004 Parkinson s Disease 707-000-04-003-H01 FLORIDA PHARMACISTS READ THIS VERY IMPORTANT CE BROKER

More information

MOVEMENT DISORDERS UPDATE H. MURRAY TODD, M.D., F.A.A.N.

MOVEMENT DISORDERS UPDATE H. MURRAY TODD, M.D., F.A.A.N. MOVEMENT DISORDERS UPDATE H. MURRAY TODD, M.D., F.A.A.N. Movement Disorders Hypokinesia : decreased voluntary and automatic movements Hyperkinesia : excessive movements HYPOKINESIAS Parkinson s disease

More information

Clinical Features and Treatment of Parkinson s Disease

Clinical Features and Treatment of Parkinson s Disease Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and

More information

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical

More information

Dr Barry Snow. Neurologist Auckland District Health Board

Dr Barry Snow. Neurologist Auckland District Health Board Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent

More information

Prior Authorization with Quantity Limit Program Summary

Prior Authorization with Quantity Limit Program Summary Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

More information

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl

More information

Tremor 101. Objectives 9/30/2015. Importance of tremors

Tremor 101. Objectives 9/30/2015. Importance of tremors Tremor 101 Umer Akbar, MD Assistant Professor, Brown University Movement Disorders Program, Rhode Island Hospital & Butler Hospital Objectives Recognize and describe the qualities of common types of tremor

More information

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz Parkinson s Disease A Guide to Medical Treatment SEEd srl. All rights reserved Piazza Carlo Emanuele II, 19 10123 Torino, Italy Tel. 011.566.02.58

More information

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders.

Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders. Lecture 5 Skeletal muscle relaxants. Pharmacologic management of parkinsonism and other movement disorders. I. SKELETAL MUSCLE RELAXANTS Skeletal muscle relaxants are pharmacologically active substances

More information

Movement disorders. Dr Rick Leventer Royal Children s Hospital

Movement disorders. Dr Rick Leventer Royal Children s Hospital Movement disorders Dr Rick Leventer Royal Children s Hospital richard.leventer@rch.org.au Movement disorders! conditions that affect the speed, fluency, quality, and ease of movement! usually affect TONE

More information

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even

More information

Damage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.

Damage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms. Lecture 20 - Basal Ganglia Basal Ganglia (Nolte 5 th Ed pp 464) Damage to the basal ganglia produces involuntary movements. Although the basal ganglia do not influence LMN directly (to cause this involuntary

More information

Visualization and simulated animations of pathology and symptoms of Parkinson s disease

Visualization and simulated animations of pathology and symptoms of Parkinson s disease Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

First described by James Parkinson in his classic 1817 monograph, An Essay on the Shaking Palsy Parkinson's Disease First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy" Parkinson s disease (PD) is a neurological disorder characterized by a progressive

More information

An Approach to Patients with Movement Disorders

An Approach to Patients with Movement Disorders An Approach to Patients with Movement Disorders Joaquim Ferreira, MD, PhD Laboratory of Clinical Pharmacology and Therapeutics Faculty of Medicine University of Lisbon EDUCATIONAL TOOLS MDS video library

More information

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1). Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease

More information

Elements for a public summary

Elements for a public summary VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Parkinson s disease affects individuals globally (WHO 2006). It is the most common serious movement disorder, including speech

More information

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral

More information

Treatment of Parkinson s Disease: Present and Future

Treatment of Parkinson s Disease: Present and Future Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing

More information

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information

PARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:

More information

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

Objectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures

Objectives. Distinguishing Parkinson s disease from other parkinsonian and tremor syndromes. Characteristics. Basal Ganglia Structures 12:45 1:30 pm PD or not PD? Distinguishing Parkinson s Disease From Other Parkinsonian and Tremor Syndromes SPEAKER Jennifer G. Goldman, MD, MS Presenter Disclosure Information The following relationships

More information

Functional Distinctions

Functional Distinctions Functional Distinctions FUNCTION COMPONENT DEFICITS Start Basal Ganglia Spontaneous Movements Move UMN/LMN Cerebral Cortex Brainstem, Spinal cord Roots/peripheral nerves Plan Cerebellum Ataxia Adjust Cerebellum

More information

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms. Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor

More information

Medications used to treat Parkinson s disease

Medications used to treat Parkinson s disease Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John

More information

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD Parkinson s Disease Initial Clinical and Diagnostic Evaluation J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported

More information

Sign up to receive ATOTW weekly -

Sign up to receive ATOTW weekly - PARKINSON S DISEASE ANAESTHESIA TUTORIAL OF THE WEEK 45 1 st FEBRUARY 2007 Dr Ritu Gupta ritugupta@doctors.org.uk MCQ s 1. During anaesthesia, a patient with Parkinson s disease on levodopa should not

More information

Hyperkinetic movement disorders are. Hyperkinetic Movement Disorders. Cases in Movement Disorders. James case. About Tom

Hyperkinetic movement disorders are. Hyperkinetic Movement Disorders. Cases in Movement Disorders. James case. About Tom Hyperkinetic Movement Disorders Sarah Furtado, MD, PhD, FRCPC James case A mother brings her son James, 10, to your office because of repetitive sniffing sounds and repetitive eye blinking. This sniffing

More information

STEADY YOUR APPROACH TO TREMOR (OVERVIEW OF DIFFERENTIAL DIAGNOSIS)

STEADY YOUR APPROACH TO TREMOR (OVERVIEW OF DIFFERENTIAL DIAGNOSIS) STEADY YOUR APPROACH TO TREMOR (OVERVIEW OF DIFFERENTIAL DIAGNOSIS) Karen M. Thomas D.O. Diplomate, ABPN Director of Movement Disorders Program Director of Comprehensive Parkinson s Disease Program Sentara

More information

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following: 1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing

More information

Dystonia: Title. A real pain in the neck. in All the Wrong Places

Dystonia: Title. A real pain in the neck. in All the Wrong Places Focus on CME at the University of Western Ontario Dystonia: Title in All the Wrong Places A real pain in the neck By Mandar Jog, MD, FRCPC and; Mary Jenkins, MD, FRCPC What is dystonia? Dystonia is a neurologic

More information

UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PHYSIOLOGY & BIOCHEMISTRY NEUROPHYSIOLOGY (MEDICAL) Spring, 2014

UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PHYSIOLOGY & BIOCHEMISTRY NEUROPHYSIOLOGY (MEDICAL) Spring, 2014 UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PHYSIOLOGY & BIOCHEMISTRY NEUROPHYSIOLOGY (MEDICAL) Spring, 2014 Textbook of Medical Physiology by: Guyton & Hall, 11 th edition 2006 Eman Al-Khateeb,

More information